Shorten your drug development cycle by identifying and characterizing neo-epitope directly from tissue using mass spectrometry
Neo-epitope discovery directly from tissue
Why predict when you can observe?
The race to identify neo-epitopes is crucial for immunology research and critical in drug and vaccine development. Universally, innovative pharmaceutical and biotech companies
recognize the power of mass spectrometry for identifying presented peptides that trigger T-cell responses. Many use predictions models to identify neo-epitopes, leading to high rates
of candidate attrition.
With NEOEPITOPE DIRECT™, neo-epitope identification is achieved directly from tissue and not from algorithms, providing observed results as opposed to predictive ones.
A shorter more reliable development cycle
A faster, efficient & more reliable pathway to discovery.
NEOEPITOPE DIRECT™ was developed based on years of mass spectrometry expertise. The naturally processed peptides isolated from tissues are identified
using LC-MS/MS. Caprion’s process of discovery, qualification, and characterization includes a comparative analysis with matched adjacent non-tumor tissue and data from our
comprehensive AntigenAtlas™ library, leading to higher quality peptide candidates for follow-up.
The optimized workflow of NEOEPITOPE DIRECT™ helps reduce material and time needed for neo-epitope identification. It’s a rigorous and reproducible solution that offers a reliable pathway to your immuno-oncology discovery. Our team of leading scientists have designed this workflow to eliminate reliance on predictive algorithms and obtain a greater variety of neo-epitopes.
Relevant neo-epitopes derived from tissues
Greater sensitivity. better mass accuracy. advanced bioinformatics.
The optimal workflow that shortens your drug development cycle
Mass Spectrometry (LC-MS/MS) is accurate and reliable: Increased sensitivity and confident peptide identification as a result of high-resolution MS/MS data.
AntigenAtlas™ is comprehensive and up-to-date: Our proprietary healthy tissue database allows better interpretation and prioritization of the data.
ELISpot is quick and efficient: Characterize immune reactivity to candidate targets in autologous or heterologous systems.
- Directly identifies naturally presented tumor antigens relative to adjacent normal tissue
- Focuses on naturally processed peptides that are presented by MHC complexes in vivo
- Reduces reliance on epitope modeling
- Better characterized candidates for follow-up
- Increased coverage of different HLA types
- Therapeutic cancer vaccines
- Adoptive T-cell therapies
- Target validation
“A robust platform that can be depended on to consistently provide high quality data run after run.”
“Peptides identified needed to meet specific length and predict affinity. Meeting these criteria indicated that the peptides identified were high quality, and could be confidently used in further analysis.”